Viromed Medical AG: Exclusive distribution partnership with AMAMUS Vet for the cold plasma medical device ViroCAP VET for veterinary use - Seite 2

"The partnership with Lang Life Sciences marks Viromed's entry into veterinary medicine - an important and growing market with around 10,000 veterinary practices and veterinary clinics in Germany alone. We were very impressed by Jan Lang and his team's many years of experience, high level of expertise and particular passion for animal welfare," says Uwe Perbandt, CEO of Viromed Medical AG. "By bringing together two pioneers in the development and application of cold plasma medicine, we are able to establish ViroCAP in the veterinary sector through a strong distribution network and provide a particularly effective and animal-friendly treatment option. In addition, the partnership with AMAMUS Vet opens opportunities for us to enter the vast veterinary U.S. market in the future.”

About ViroCAP

ViroCAP is a portable medical device for the treatment of skin diseases using cold atmospheric plasma (CAP). ViroCAP is expected to be certified as a medical device in 2025. ViroCAP inactivates viruses, bacteria, multi-resistant pathogens and fungi and therefore the cause of many skin diseases. At the same time, the cold plasma stimulates cell biological mechanisms, thereby activating cell division, blood circulation and cell metabolism.

About cold atmospheric plasma

Cold atmospheric plasma is an innovative physical, completely painless treatment method, that destroys viruses and bacteria in the respiratory tract in 30-90 seconds. Cold plasma is a groundbreaking innovation, particularly effective against antibiotic-resistant MRSA bacteria, as it destroys them. Antibiotics can take several hours or even days to reach the source of an infection and are becoming increasingly ineffective due to the growing problem of multi-resistant germs. The use of cold plasma against VAP has the potential to reduce infections, accelerate healing, decrease antibiotic usage and, above all, save hundreds of thousands of lives every year.

About Viromed Medical AG

Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of the innovative cold plasma technology for medical applications through its wholly owned subsidiary Viromed Medical GmbH. In doing so, Viromed can draw on a broad customer base in the DACH region. Viromed Medical AG aims to further advance the use of CAP in medicine in the coming years and to realize corresponding growth potential.